Skip to main content
. 2020 Jan 25;25(3):527. doi: 10.3390/molecules25030527

Table 2.

Results of the five-dose in vitro human cancer cell growth inhibition a for Compound 11c and control phenstatin.

Cell Type Compound→ 11c Phenstatin
Cell Line↓ GI50 (μM) b
Leukemia HL-60(TB) 2.78 0.011
SR 0.807 <0.010
CCRF-CEM 3.13 0.034
Non-small
Cell Lung Cancer
NCI-H460 1.58 0.033
NCI-H522 0.611 0.027
HOP-62 3.78 0.073
Colon Cancer HCT-116 0.619 0.038
HCT-15 1.25 <0.010
HT29 1.42 2.95
SW-620 0.930 <0.010
KM12 1.30 <0.010
CNS Cancer SF-295 0.800 0.367
SF-539 2.10 0.011
SNB-75 2.04 <0.010
U251 3.61 0.043
Melanoma SK-MEL-5 0.836 0.040
M14 0.648 <0.010
MDA-MB-435 0.296 <0.010
UACC-62 0.918 0.448
LOXIMVI 2.60 0.013
MALME-3M 1.24 -
SK-MEL-2 2.67 0.520
SK-MEL-28 3.70 65.20
Ovarian Cancer OVCAR-3 1.08 0.021
NCI/ADR-RES 0.948 0.012
IGROV1 2.33 0.18
OVCAR-8 3.73 0.042
Renal Cancer 786-0 2.34 0.905
A498 2.82 2.28
UO-31 0.891 0.074
ACHN 2.40 0.042
RXF 393 2.06 0.016
Breast cancer MCF7 2.25 0.033
HS 578T 3.04 0.031
MDA-MB-231/ATCC 2.66 0.029
BT-549 1.94 0.034
T-47D 2.37 30.4
MDA-MB-468 2.83 2.71
Prostate cancer PC-3 0.960 0.045
DU-145 3.44 0.039

a Data obtained from NCI’s in vitro 60 cell five-dose screening. b GI50 – the molar concentration of tested compound causing 50% growth inhibition of tumor cells.